Treatment of RTK-driven cancer cell lines with zotatifin for 24 h resulted in dose dependent downregulation of HER2, FGFR1 and FGFR2 protein levels, as well as cyclin D1 (a zotatifin target gene (6), Figure 1C, Supplementary Figure S1A). Here, CCND1 is linked to cancer.